| (Values in U.S. Thousands) | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 | Jun, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -50,990 | -100,670 | -83,040 | -60,380 | -44,670 |
| Net Income Growth | +49.35% | -21.23% | -37.53% | -35.17% | -15.43% |
Adagio Therapeutics Inc (ADGI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Adagio Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. Adagio Therapeutics Inc. is based in WALTHAM, Mass.
Fiscal Year End Date: 12/31